IL4 and cancer: Knowledge of the details of the recognition mechanism will finally allow highly specific growth factors to be designed that are able to distinguish between different receptor combinations, as shown for the T-cell specific IL-4 antagonist IL-4R121E [63,64] or the IL-13 cytotoxin fusion used for treatment of several cancers [65,66].